ArticleCurrent medicinal chemistry2026
Establishment of Centrosome Amplification-Correlated Model to Evaluate the Tumor Immune Microenvironment and Prognosis of Patients with Glioblastoma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionCentrosome Amplification (CA) is a state where malignant cells contain excessive centrosomes due to cell cycle dysregulation. Altered CA has been observed in Glioblastoma (GBM). This study developed a CA-related gene model to assess the Tumor Immune Microenvironment (TIME) and prognostic outcomes for patients with GBM.
methodsTCGA-GBM and mRNAseq_325 cohorts were obtained from the Chinese Glioma Genome Atlas (CGGA) database. CA-relevant gene modules and feature genes were identified via WGCNA analysis. Key genes were selected to develop a risk model, followed by validation of the model's performance. We further compared the gene mutation landscape, TIME characteristics, drug sensitivity, and enriched pathways between high- and low-risk patient groups.
resultsThe brown module, which showed the highest correlation with CA, was selected to identify CA-related key genes to develop a Riskscore model. The model can accurately categorize patients into high- and low-risk groups and predict their clinical outcomes with precision. Notably, high-risk GBM patients exhibited higher StromalScore and dendritic score, and the Riskscore was positively correlated with fibroblast infiltration. Moreover, patients with different risk levels displayed distinct enriched pathways and gene mutation landscapes. Further, the high-risk group showed an evidently higher CAF score, and the differential relation between drug sensitivity and the Riskscore was detected. DISCUSSION: Though CA was altered in GBM, its prognostic utility remained to be explored. The current study addressed this gap by developing a 6-gene risk model capable of predicting the prognosis and TIME of GBM patients.
conclusionA CA-related model was constructed to assess the prognosis and TIME of GBM patients, contributing to the management of GBM in clinical practice.
Indexed as
Identifiers
41568471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.